Small Extracellular Vesicles as a New Class of Medicines

Authors
Lee, InkyuChoi, YoonjeongShin, Dong-UKwon, MinjeongKim, SeohyunJung, HanulNam, Gi-HoonKwon, Minsu
Issue Date
2023-02
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Citation
Pharmaceutics, v.15, no.2
Abstract
Extracellular vesicles (EVs) are nanovesicles that are naturally released from cells in a lipid bilayer-bound form. A subset population with a size of 200 nm, small EVs (sEVs), is enticing in many ways. Initially perceived as mere waste receptacles, sEVs have revealed other biological functions, such as cell-to-cell signal transduction and communication. Besides their notable biological functions, sEVs have profound advantages as future drug modalities: (i) excellent biocompatibility, (ii) high stability, and (iii) the potential to carry undruggable macromolecules as cargo. Indeed, many biopharmaceutical companies are utilizing sEVs, not only as diagnostic biomarkers but as therapeutic drugs. However, as all inchoate fields are challenging, there are limitations and hindrances in the clinical translation of sEV therapeutics. In this review, we summarize different types of sEV therapeutics, future improvements, and current strategies in large-scale production.
Keywords
ENGINEERING EXOSOMES; ANTITUMOR-ACTIVITY; CELLS; DELIVERY; PACLITAXEL; ENDOCYTOSIS; ACTIVATION; PROMOTE; VACCINE; LIGHT; small extracellular vesicle; exosome; naive small extracellular vesicle; engineered small extracellular vesicle; a new class of medicine
ISSN
1999-4923
URI
https://pubs.kist.re.kr/handle/201004/114010
DOI
10.3390/pharmaceutics15020325
Appears in Collections:
KIST Article > 2023
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE